In terms of the recurrence number of the allergic asthma participants and the ACT score, allergic asthma also improved at 18 and 30 weeks of the trial, which may be related to the changes of the levels of IgE, Th1 and Th2 cells, IFN-γ, and IL-4 cytokine. The gene discussed is IL4; the disease is allergic asthma.